New combo aims to shrink bile duct tumors before surgery
NCT ID NCT07599995
First seen May 22, 2026 · Last updated May 22, 2026
Summary
This study tests whether adding the drug envafolimab to standard chemotherapy (gemcitabine and cisplatin) before surgery can reduce cancer cells in patients with bile duct cancer at high risk of coming back. About 34 adults aged 18-80 with this cancer will receive the drug combination, then have their tumor tissue checked after surgery. The main goal is to see if the treatment leaves 10% or fewer live tumor cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.